Angiotensin 1-7 Modulates the Dynamics and Activation of the Proto-oncogene Mas Receptor

Read the full article See related articles

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

The proto-oncogene Mas receptor (MasR, UniProt ID: P04201) is a class-A (orphan-type) G protein-coupled receptor (GPCR) that mediates the protective effects of Angiotensin 1-7 (Ang 1-7) within the renin–angiotensin system (RAS). Despite its therapeutic relevance, the molecular mechanisms underlying MasR activation by Ang 1-7 remain elusive due to the lack of experimental structural data. In this study, we performed 1-microsecond all-atom molecular dynamics (MD) simulations of AlphaFold-modeled active and inactive MasR conformations, with and without Ang 1-7, to characterize ligand-induced conformational dynamics.

Ang 1-7 binding led to increased interaction stability in the active state, reflected by higher occupancy of hydrogen bonds, salt bridges, and hydrophobic contacts. Structural analyses revealed reduced RMSD/RMSF values and stabilization of key transmembrane (TM) helices and the NPxxY micro-switch. TM distance and dihedral analyses indicated partial TM6 displacement and time-dependent NPxxY reorganization. Network-based metrics including betweenness centrality and shortest path length highlighted the emergence of state-specific communication hubs, while PCA, correlation and communication propensity analyses revealed enhanced conformational diversity and selective inter-residue signaling in the ligand-bound state. Molecular mechanics Poisson–Boltzmann surface area (MM/PBSA) calculations showed favorable binding energetics in the active state (ΔG Bind = –13.99 kcal/mol).

These results demonstrate that Ang 1-7 acts as a partial agonist of MasR by stabilizing the inactive conformation while inducing limited activation features in the active state through non-canonical micro-switch dynamics. This work advances structural insights into MasR regulation and provides a foundation for therapeutic targeting of the ACE2/Ang 1-7/MasR axis.

Article activity feed